Spatial transcriptomics, spatial proteomics, and mass spectrometry imaging are converging fast. Researchers can now map gene and protein expression directly inside intact tissue, something no bulk, homogenized sample could ever show them. That’s a genuine scientific breakthrough.
It is not, on its own, a commercial strategy.
If you’re building or selling into spatial biology (instruments, consumables, sample prep kits, validated antibody panels, or analysis software) you already know the technical story sells itself to the first few labs. The problem shows up after that: how do you turn early scientific interest into a predictable revenue, when your buyers are split between core facilities, individual PIs, and pharma translational teams who all evaluate completely differently?
That’s the commercial layer PSG Life Sciences builds.
Why spatial biology is the wrong market to sell into generically
Spatial biology platforms are under growing pressure to prove they deliver more than a high-resolution picture, buyers want to know the data translates into a usable biomarker or treatment decision. A handful of large platform vendors already dominate the core instrument layer. If your positioning sounds like theirs, “compatible with leading spatial platforms,” “high-resolution multi-omics mapping”, you’re competing on their budget, not your strength.
The companies winning in this category right now are the ones that own a specific tissue type, a specific failure mode, or a specific workflow stage. A fixation kit that prevents degraded RNA in fresh-frozen tumor sections. A QC step that flags a bad section before it wastes an expensive spatial run. That’s a sales conversation a core facility director actually wants to have.
Where PSG Life Sciences fits
PSG Life Sciences works inside the analytical technologies and cell biology markets every day, chromatography, mass spectrometry, multiplex assay systems, and the 3D culture and microphysiological systems that increasingly sit alongside spatial workflows. We don’t need an explainer on what spatial biology is. We need to know what makes your specific product worth switching to.
If you’re early and still finding product-market fit, our Start solution builds the ideal customer profile, positioning, and go-to-market plan grounded in real buyer data, not a generic spatial biology pitch deck.
If you have traction and need to scale past your first wave of customers, our Grow solution builds the CRM-driven sales and marketing system that turns scattered early adoption into a repeatable pipeline, segmented by tissue type, application, and whether the buyer is a core facility, an individual lab, or a pharma translational team.
If HubSpot is already your CRM, or you know it should be, HubSpot Life Sciences Pro configures it specifically for spatial biology sales cycles, sample tracking, platform-compatibility segmentation, and core-facility account management built in, not bolted on.
What we actually build for spatial biology and multi-omics companies
- Workflow-specific positioning that names the tissue type, the failure mode prevented, and the platform compatibility
- CRM segmentation by platform compatibility, tissue/application area, and buyer type (core facility vs. individual lab vs. pharma)
- Sample and trial request workflows that treat every request as a qualified commercial event, with automated follow-up instead of a black hole
- Distributor and channel structure where it makes sense, with shared target lists and visible pipeline instead of a passive referral relationship
- Content and proof — application notes and comparison data built for the specific disease areas your buyers actually work in
A direct question worth asking yourself
Where does your product sit in the spatial workflow, are you trying to compete with the instrument makers, or are you the thing that makes their instrument actually work reliably on a real, messy clinical sample? Most companies that win in this category have already answered that question. The ones still growing slowly usually haven’t.
Ready to turn your spatial biology company into a commercial engine?
PSG Life Sciences is a HubSpot Gold partner and fractional commercialization firm working exclusively with biotech, life science, and diagnostic product companies, including the analytical and cell biology platforms spatial biology depends on. We build the positioning, CRM, and demand generation systems described above as implemented client work, not theory.